Alexander Charles Ford (Alexander Ford, A C Ford, Alexander C Ford)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 112

Top Venues

Alimentary pharmacology & therapeutics

Gut

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society

Frontline gastroenterology

This page only lists publications with an associated author ORCID identifier.

Publications

Vivek C Goodoory, Elspeth A Guthrie, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply. Alimentary pharmacology & therapeutics 57 (10) (2023)
Christy Riggott, Keeley M Fairbrass, Christopher J Black, David J Gracie, Alexander Charles Ford
Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study. Alimentary pharmacology & therapeutics (2023)
Vivek C Goodoory, Cho E Ng, Christopher J Black, Alexander Charles Ford
Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome. Alimentary pharmacology & therapeutics (2023)
Vivek C Goodoory, Elspeth A Guthrie, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply. Alimentary pharmacology & therapeutics 57 (10) (2023)
Hussain Jaafari, Lesley A Houghton, Robert M West, Anurag Agrawal, Imran Aziz, Christopher J Black, Maura Corsetti, Farag Shuweihdi, Maria Eugenicos, Peter A Paine, Alexander Charles Ford, Peter J Whorwell, Shrikant I Bangdiwala, Olafur S Palsson, Ami D Sperber, Dipesh Harshvadan Vasant
The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2023)
David Gunn, Alexander Charles Ford, Amanda Farrin, Robin C Spiller
Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply. Alimentary pharmacology & therapeutics 57 (11) (2023)
David Gunn, Alexander Charles Ford, Amanda Farrin, Robin C Spiller
Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply. Alimentary pharmacology & therapeutics 57 (11) (2023)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply. Alimentary pharmacology & therapeutics 57 (10) (2023)
Vivek C Goodoory, Cho E Ng, Christopher J Black, Alexander Charles Ford
Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome-authors' reply. Alimentary pharmacology & therapeutics 58 (1) (2023)
Vivek C Goodoory, Elspeth A Guthrie, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply. Alimentary pharmacology & therapeutics 57 (10) (2023)
Kee-Huat Chuah, Christopher J Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong Yeh Lee, Sanjiv Mahadeva, Alexander Charles Ford
Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply. Alimentary pharmacology & therapeutics 58 (4) (2023)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply. Alimentary pharmacology & therapeutics 57 (10) (2023)
Vivek C Goodoory, Elspeth A Guthrie, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply. Alimentary pharmacology & therapeutics 57 (10) (2023)
Kee-Huat Chuah, Christopher J Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong Yeh Lee, Sanjiv Mahadeva, Alexander Charles Ford
A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care. Alimentary pharmacology & therapeutics (2023)
David Gunn, Rabia Topan, Lorna Barnard, Ron Fried, Ivana Holloway, Richard Brindle, Maura Corsetti, Mark Scott, Adam Farmer, Kapil Kapur, David Sanders, Maria Eugenicos, Nigel Trudgill, Peter Whorwell, John T McLaughlin, Ayesha Akbar, Lesley A Houghton, Phil G Dinning, Qasim Aziz, Alexander Charles Ford, Amanda J Farrin, Robin C Spiller
Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary pharmacology & therapeutics (2023)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply. Alimentary pharmacology & therapeutics 57 (10) (2023)
Brigida Barberio, David J Gracie, Christopher J Black, Alexander Charles Ford
Impact of Baseline Disease Activity and Trial Duration on Efficacy of Biologics in Active Crohn's Disease: Meta-analysis. Inflammatory bowel diseases (2023)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply. Alimentary pharmacology & therapeutics 57 (10) (2023)
Brigida Barberio, Keeley M Fairbrass, David J Gracie, Alexander Charles Ford
Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 12 months of longitudinal follow-up. Neurogastroenterology and motility (2023)
Vivek C Goodoory, Elspeth A Guthrie, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply. Alimentary pharmacology & therapeutics 57 (6) (2023)
Christy Riggott, Keeley M Fairbrass, Christian P Selinger, David J Gracie, Alexander Charles Ford
Impact of Opioid Use on the Natural History of Inflammatory Bowel Disease: Prospective Longitudinal Follow-up Study. Inflammatory bowel diseases (2023)
Pierfrancesco Visaggi, Brigida Barberio, Giulio Del Corso, Nicola de Bortoli, Christopher J Black, Alexander Charles Ford, Edoardo Vincenzo Savarino
Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis. Gut (2023)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Alimentary pharmacology & therapeutics 56 (1) (2022)
Shahida Din, Christian P Selinger, Christopher J Black, Alexander Charles Ford
Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Alimentary pharmacology & therapeutics 57 (6) (2022)
Vivek C Goodoory, Elspeth A Guthrie, Cho E Ng, Christopher J Black, Alexander Charles Ford
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Alimentary pharmacology & therapeutics 57 (3) (2022)
Christopher J Black, Lesley A Houghton, Alexander Charles Ford
Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 34 (11) (2022)
Vivek C Goodoory, Elspeth A Guthrie, Cho E Ng, Christopher J Black, Alexander Charles Ford
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Alimentary pharmacology & therapeutics 57 (3) (2022)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Alimentary pharmacology & therapeutics 56 (5) (2022)
Shahida Din, Christian P Selinger, Christopher J Black, Alexander Charles Ford
Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Alimentary pharmacology & therapeutics 57 (6) (2022)
Brigida Barberio, Sonia Facchin, Ilaria Patuzzi, Alexander Charles Ford, Davide Massimi, Giorgio Valle, Eleonora Sattin, Barbara Simionati, Elena Bertazzo, Fabiana Zingone, Edoardo Vincenzo Savarino
A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach. Gut microbes 14 (1) (2022)
Shahida Din, Christian P Selinger, Christopher J Black, Alexander Charles Ford
Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Alimentary pharmacology & therapeutics (2022)
Keeley M Fairbrass, P John Hamlin, David J Gracie, Alexander Charles Ford
Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply. Alimentary pharmacology & therapeutics 56 (8) (2022)
Maria Rosa Ingrosso, Gianluca G Ianiro, Judy W Nee, Anthony J Lembo, Paul Moayyedi, Christopher J Black, Alexander Charles Ford
Letter: efficacy of peppermint oil in irritable bowel syndrome-authors' reply. Alimentary pharmacology & therapeutics 56 (7) (2022)
Christopher J Black, Alexander Charles Ford
Letter in response to Black et al. (2020): Authors' Reply. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 34 (6) (2022)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply. Alimentary pharmacology & therapeutics 55 (12) (2022)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2022)
Alexander Charles Ford, Evangelos Tsipotis, Yuhong Yuan, Grigorios I Leontiadis, Paul Moayyedi
Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis. Gut (2022)
Brigida Barberio, Pierfrancesco Visaggi, Edoardo Vincenzo Savarino, Nicola de Bortoli, Christopher J Black, Alexander Charles Ford
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2022)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' reply. Alimentary pharmacology & therapeutics 56 (5) (2022)
Christopher J Black, Peter A Paine, Anurag Agrawal, Imran Aziz, Maria P Eugenicos, Lesley A Houghton, Pali Hungin, Ross Overshott, Dipesh H Vasant, Sheryl Rudd, Richard C Winning, Maura Corsetti, Alexander Charles Ford
British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut 71 (9) (2022)
Maria Rosa Ingrosso, Gianluca G Ianiro, Judy W Nee, Anthony J Lembo, Paul Moayyedi, Christopher J Black, Alexander Charles Ford
Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Alimentary pharmacology & therapeutics 56 (6) (2022)
Vivek C Goodoory, Elspeth A Guthrie, Cho E Ng, Christopher J Black, Alexander Charles Ford
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Alimentary pharmacology & therapeutics (2022)
Vivek C Goodoory, Elspeth A Guthrie, Cho E Ng, Christopher J Black, Alexander Charles Ford
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Alimentary pharmacology & therapeutics 57 (3) (2022)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. Alimentary pharmacology & therapeutics 55 (10) (2022)
Vivek C Goodoory, Elspeth A Guthrie, Cho E Ng, Christopher J Black, Alexander Charles Ford
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Alimentary pharmacology & therapeutics 57 (3) (2022)
Shahida Din, Christian P Selinger, Christopher J Black, Alexander Charles Ford
Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Alimentary pharmacology & therapeutics 57 (6) (2022)
Keeley M Fairbrass, P John Hamlin, David J Gracie, Alexander Charles Ford
Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up. Alimentary pharmacology & therapeutics 56 (8) (2022)
Conchubhair Winters, Alexander Charles Ford
Immortal time bias in a retrospective study examining colorectal cancer mortality according to adherence to colonoscopy. Gut 72 (9) (2022)
Vivek C Goodoory, Cho Ee Ng, Christopher J Black, Alexander Charles Ford
Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply. Alimentary pharmacology & therapeutics 55 (9) (2022)
Brigida Barberio, David J Gracie, Christopher J Black, Alexander Charles Ford
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. Gut (2022)
Alfred D Nelson, Christopher J Black, Lesley A Houghton, Nahyr Sofía Lugo-Fagundo, Brian E Lacy, Alexander Charles Ford
Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating-a step in the right direction for targeted treatment? Authors' reply. Alimentary pharmacology & therapeutics 54 (2) (2021)
Keeley M Fairbrass, Jessica Lovatt, Brigida Barberio, Yuhong Yuan, David J Gracie, Alexander Charles Ford
Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. Gut (2021)
Vivek C Goodoory, Orla F Craig, David J Gracie, Christopher J Black, Alexander Charles Ford
Prognosis of patients with Rome IV-defined versus physician-diagnosed irritable bowel syndrome: Longitudinal follow-up study. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2021)
Keeley M Fairbrass, David J Gracie, Alexander Charles Ford
Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease. Alimentary pharmacology & therapeutics 54 (4) (2021)
Keeley M Fairbrass, Christian P Selinger, David J Gracie, Alexander Charles Ford
Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2021)
Maura Corsetti, Steven Brown, Giuseppe Chiarioni, Eirini Dimidi, Thomas Dudding, Anton Emmanuel, Mark R Fox, Alexander Charles Ford, Pasquale Giordano, Ugo Grossi, Michelle Henderson, Charles H Knowles, P Ronan O'Connell, Eamonn M M Quigley, Magnus Simren, Robin C Spiller, Kevin Whelan, William E Whitehead, Andrew B Williams, S Mark Scott
Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 33 (7) (2021)
Christopher J Black, Heidi M Staudacher, Alexander Charles Ford
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut (2021)
Nicholas E Burr, David J Gracie, Christopher J Black, Alexander Charles Ford
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut (2021)
Leonardo Henry Umberto Eusebi, Andrea Telese, Giovanna G Cirota, Rehan Haidry, Rocco Maurizio Zagari, Franco Bazzoli, Alexander Charles Ford
Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms. Alimentary pharmacology & therapeutics 53 (9) (2021)
Tim Klaassen, Fabiënne G M Smeets, Lisa Vork, Tack Jan, Nicholas J Talley, Magnus Simrén, Qasim Aziz, Alexander Charles Ford, Joanna W Kruimel, José M Conchillo, Carsten Leue, Adrian A M Masclee, Daniel Keszthelyi
Psychometric evaluation of an experience sampling method-based patient-reported outcome measure in functional dyspepsia. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 33 (9) (2021)
Alfred D Nelson, Christopher J Black, Lesley A Houghton, Nahyr Sofía Lugo-Fagundo, Brian E Lacy, Alexander Charles Ford
Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. Alimentary pharmacology & therapeutics 54 (2) (2021)
Dipesh Harshvadan Vasant, Peter A Paine, Christopher J Black, Lesley A Houghton, Hazel A Everitt, Maura Corsetti, Anurag Agrawal, Imran Aziz, Adam D Farmer, Maria P Eugenicos, Rona Moss-Morris, Yan Yiannakou, Alexander Charles Ford
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 70 (7) (2021)
Brigida Barberio, Christopher J Black, Alexander Charles Ford
Editorial: will clusters for anxiety, depression, sleep disturbance and fatigue symptoms predict treatment outcomes in functional dyspepsia? Authors' reply. Alimentary pharmacology & therapeutics 53 (5) (2021)
Mohammad Zamani, Shaghayegh Alizadeh-Tabari, Amir Hossein Hasanpour, Leonardo H Eusebi, Alexander Charles Ford
Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications. Alimentary pharmacology & therapeutics 54 (8) (2021)
Christopher J Black, Yan Yiannakou, Elspeth Guthrie, Robert West, Lesley A Houghton, Alexander Charles Ford
Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. Alimentary pharmacology & therapeutics 53 (10) (2021)
Vivek C Goodoory, Lesley A Houghton, Christopher J Black, Alexander Charles Ford
Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2021)
Christopher J Black, Alexander Charles Ford
Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management-authors' reply. Alimentary pharmacology & therapeutics 53 (10) (2021)
Brigida Barberio, Edoardo Vincenzo Savarino, Christopher J Black, Alexander Charles Ford
Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2021)
Christopher J Black, Alexander Charles Ford
How effective are antibiotics for the treatment of irritable bowel syndrome? Expert opinion on pharmacotherapy 21 (18) (2020)
Christopher J Black, Alexander Charles Ford
Faecal incontinence is not rare in irritable bowel syndrome. Frontline gastroenterology 11 (6) (2020)
Keeley M Fairbrass, Deloar Hoshen, David J Gracie, Alexander Charles Ford
Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease. Gut 70 (1) (2020)
Antonina Mikocka-Walus, Alexander Charles Ford, Douglas A Drossman
Antidepressants in inflammatory bowel disease. Nature reviews. Gastroenterology & hepatology 17 (3) (2020)
Gianluca G Ianiro, Serena Porcari, Alexander Charles Ford, Antonio Gasbarrini, Giovanni Cammarota
Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement. Alimentary pharmacology & therapeutics 52 (5) (2020)
Alexander Charles Ford, Yuhong Yuan, Paul Moayyedi
Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 69 (12) (2020)
Christopher J Black, Yan Yiannakou, Lesley A Houghton, Farag Shuweihdi, Robert West, Elspeth Guthrie, Alexander Charles Ford
Anxiety-related factors associated with symptom severity in irritable bowel syndrome. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 32 (8) (2020)
Alexander Charles Ford, Paul Moayyedi, Christopher J Black, Yuhong Yuan, Sajesh K Veettil, Sanjiv Mahadeva, Kirati Kengkla, Nathorn Chaiyakunapruk, Yeong Yeh Lee
Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Alimentary pharmacology & therapeutics 53 (1) (2020)
Alexander Charles Ford, Lucinda A Harris, Brian E Lacy, Eamonn M M Quigley, Paul Moayyedi
Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply. Alimentary pharmacology & therapeutics 49 (9) (2020)
Christopher J Black, Alexander Charles Ford, Lesley A Houghton
Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer? Alimentary pharmacology & therapeutics 50 (7) (2020)
S Mark Scott, Magnus Simrén, Adam Donald Farmer, Philip G Dinning, Emma V Carrington, Marc A Benninga, Rebecca E Burgell, Eirini Dimidi, Asma Fikree, Alexander Charles Ford, Mark R Fox, Caroline L Hoad, Charles H Knowles, Klaus Krogh, Karen Nugent, José María Remes-Troche, Kevin Whelan, Maura Corsetti
Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 33 (6) (2020)
Christopher J Black, Brigida Barberio, Alexander Charles Ford
Editorial: minesapride for irritable bowel syndrome with constipation. Alimentary pharmacology & therapeutics 52 (4) (2020)
Christian Philipp Selinger, Jenelyn Carbonell, John S Kane, Mandour Omer, Alexander Charles Ford
Acceptability of a 'treat to target' approach in inflammatory bowel disease to patients in clinical remission. Frontline gastroenterology 12 (1) (2020)
Leonardo Henry Umberto Eusebi, Giovanna Grazia Cirota, Rocco Maurizio Zagari, Alexander Charles Ford
Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis. Gut 70 (3) (2020)
Christopher J Black, Alexander Charles Ford
Best management of irritable bowel syndrome. Frontline gastroenterology 12 (4) (2020)
Brigida Barberio, Maria Ines Pinto-Sanchez, Premysl Bercik, Ruchit Sood, Edoardo V Savarino, Paul Moayyedi, Christopher J Black, Alexander Charles Ford
Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. Alimentary pharmacology & therapeutics 53 (2) (2020)
Alexander Charles Ford
Commentary: estimating the prevalence of IBS globally-past, present and future. Alimentary pharmacology & therapeutics 51 (1) (2020)
Christopher J Black, Elyse R Thakur, Lesley A Houghton, Eamonn M M Quigley, Paul Moayyedi, Alexander Charles Ford
Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut 69 (8) (2020)
Brigida Barberio, Sanjiv Mahadeva, Christopher J Black, Edoardo V Savarino, Alexander Charles Ford
Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. Alimentary pharmacology & therapeutics 52 (5) (2020)
Christopher J Black, Orla Craig, David J Gracie, Alexander Charles Ford
Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut 70 (6) (2020)
Irene X Y Wu, Charlene Hoi-Lam Wong, Robin S T Ho, William K W Cheung, Alexander Charles Ford, Justin C Y Wu, Arthur D P Mak, Holger Cramer, Vincent C H Chung
Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. Therapeutic advances in gastroenterology 12 (2019)
Gianluca G Ianiro, Leonardo Henry Umberto Eusebi, Christopher J Black, Antonio Gasbarrini, Giovanni Cammarota, Alexander Charles Ford
Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Alimentary pharmacology & therapeutics 50 (3) (2019)
J Shearer, P Paine, A Agrawal, Alexander Charles Ford
Efficacy of linaclotide in irritable bowel syndrome with constipation: Real-world data. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 30 (5) (2019)
Leonardo H Eusebi, Christopher J Black, Colin W Howden, Alexander Charles Ford
Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. BMJ (Clinical research ed.) 367 (2019)
Christopher J Black, Alexander Charles Ford
Rational investigations in irritable bowel syndrome. Frontline gastroenterology 11 (2) (2019)
Christopher J Black, Nicholas E Burr, Michael Camilleri, David L Earnest, Eamonn Mm Quigley, Paul Moayyedi, Lesley A Houghton, Alexander Charles Ford
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut 69 (1) (2019)
Shujing Jane Lim, David J Gracie, John S Kane, Saqib Mumtaz, Andrew F Scarsbrook, Fahmid U Chowdhury, Alexander Charles Ford, Christopher J Black
Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow-up study. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 31 (9) (2019)
Pavit Luthra, Nicholas E Burr, Darren M Brenner, Alexander Charles Ford
Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. Gut 68 (3) (2018)
Nicholas E Burr, Alexander Charles Ford
Assessing the efficacy of peripherally acting µ-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. Gut 68 (8) (2018)
Christopher J Black, Lesley A Houghton, Alexander Charles Ford
Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. Therapeutic advances in gastroenterology 11 (2018)
Fabiënne G M Smeets, Daniel Keszthelyi, Lisa Vork, Jan Tack, Nicholas J Talley, Magnus Simren, Qasim Aziz, Alexander Charles Ford, José M Conchillo, Joanna W Kruimel, Jim Van Os, Ad A M Masclee
Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 31 (2) (2018)
Alexander Charles Ford, Lucinda A Harris, Brian E Lacy, Eamonn M M Quigley, Paul Moayyedi
Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Alimentary pharmacology & therapeutics 48 (10) (2018)

Alexander Charles Ford.css-eqlu8i{font-size:small;padding-left:4px;} (Alexander Ford, A C Ford, Alexander C Ford)

Publication Activity (10 Years)

Top Topics

Top Venues

Alexander Charles Ford (Alexander Ford, A C Ford, Alexander C Ford)